SafePharm Labs Logo
Login
Password
Sign Up Here Lost Password?
 
Testing Services
 
Biodegradation
Aquatic Studies
Endocrine Disruptors
Analytical Support
dots
line  
rcc logo and website link
harlan logo and website
harlan europe logo and website
harlan teklad

To view the documents within this site you will need to have or download

For a list of commonly used abbreviations please download.

word

Ecotoxicology - Endocrine Disruptors
  • In Vitro Screening Test For Oestrogenic Activity

The Department of Ecotoxicology has validated a sensitive and specific in vitro screening test for oestrogenic chemicals using a recombinant yeast assay. This assay allows for the generation of reproducible empirical biological data to be obtained in a cost-and-time-effective manner.

A simple colour change from yellow to red, measured by a spectrophotometer, indicated the presence of an oestrogenic chemical. The intensity of the colour change is directly related to the oestrogenic activity. This assay has been shown to be suitable for both neat chemicals and environmental samples and complements the in vivo mammalian methods also available at SPL.

A similar assay for androgenic activity has also been validated. The Department now offers a full range of oestrogen, androgen, anti-oestrogen and anti-androgen screens.


  • In Vivo Endocrine Disruption Assay

An in vivo assay to screen for potential oestrogenic activity has been developed by the department of reproductive toxicology. The assay is a version of the uterotrophic assay and is currently in use for a number of our current clients.

The assay involves the administration of a test material to the intact juvenile female rat for three consecutive days. The uterus is examined, excised and weighed. An increased uterine weight as a result of fluid imbibition is noted. Fluid imbibition is a characteristic effect of an oestrogenic test material on the uterus. The use of an intact juvenile obviates the need for surgical intervention in an adult rat to achieve the same physiological status. Results of these assays are supported by the inclusion of a positive control (diethystibestrol). It is also possible to evaluate any synergistic effects by administration of an unknown test material with the positive control.

The combination of this in vivo screening assay together with existing in vitro assays available at SafePharm provides the basis of a battery of assays to evaluate potential endocrine disruption.

References
Routledge E J and Sumpter J P 1996. Environmental Toxicology and Chemistry 15 p241-248
Schultz T W et al 1998. Environmental Toxicology and Chemistry 17 p1727-1729

Acknowledgements
The recombinant yeast strain was developed by GlaxoWellcome Research and Development. The training in the use of the assay was provided by Professor John Sumpter and his colleagues at Brunel University, England.

 
This site is best viewed with Internet Explorer 6.0+ or Netscape Navigator 7+, at a minimum screen resolution of 800 x 600, and a minimum modem connection speed of 56Kbps.
Copyright © SafePharm Laboratories 2006-2007. All rights reserved. //
terms & conditions // website design trondez.com